Jared is a freelance writer for The American Journal of Managed Care® (AJMC®), and previously worked as a senior editor for HCPLive® at MJH Life Sciences®.
He has an MA from University of Sioux Falls. You can connect with Jared on LinkedIn.
Case Series Highlights Bacillus Cereus Risk in Patients With AML, Neutropenia
March 12th 2024Introducing ciprofloxacin to their institution’s empiric antimicrobial regimen for patients with AML and prolonged or recurrent neutropenic fevers appeared to reduce the risk of Bacillus cereus infection.
Read More
Combination Therapies Provide Optimal Hypertensive Control in Patients Taking Ibrutinib
February 17th 2024The retrospective study found patients on Bruton’s tyrosine kinase inhibitors are similar to the general population in the sense that it usually takes at least 2 anti-hypertensive drugs to control blood pressure.
Read More
Targeted Therapy Associated With Lower SPM Risk Among Treated Patients With CLL
February 6th 2024Investigators found patients receiving chemotherapy had a greater risk of a secondary primary malignancy (SPM) compared with those treated with targeted therapies or those whose chronic lymphocytic leukemia (CLL) was left untreated.
Read More
Retrospective Analysis Suggests Allo-HSCT Feasible for R/R DLBCL After CAR T Failure
January 30th 2024Among the 10 patients in the retrospective analysis, the median overall survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) was 21 months.
Read More
ELN Risk Category, MRD Status Predictive of Relapse in Patients With AML
January 29th 2024The study may help explain why some patients are more prone to relapse following a complete response to induction therapy, as indicated by measurable residual disease (MRD) status and 2017 European LeukemiaNet (ELN) criteria.
Read More